| Autor: |
Holly A R, Wiesinger, J, Shah, A, White, E M, Yoshida, J, Frohlich, S, Sirrs, S, Gill, M F, Byrne |
| Rok vydání: |
2008 |
| Předmět: |
|
| Zdroj: |
Annals of hepatology. 7(1) |
| ISSN: |
1665-2681 |
| Popis: |
The metabolic syndrome and non-alcoholic fatty liver disease are increasing at alarming rates.To determine the effect of HMG-CoA reductase inhibitors (statins) on elevated liver enzymes in patients with hyperlipidemia.Patients with AST above 60 U/L prior to or during treatment with statin therapy at a quaternary care lipid clinic were reviewed.A retrospective analysis was conducted. Patients were separated into two groups: Group 1--elevated AST prior to statin therapy; and Group 2--elevated AST during statin therapy.Forty six patients with one or more measurements of AST60 U/L remained after exclusion criteria were applied. Ten of 13 (77%) group 1 patients had reduced AST levels after initiation of statin therapy. Thirty two of 33 patients (97%) in group 2 had transient AST elevations while on statin therapy; one patient had persistently elevated AST after initiation of treatment. There were no significant adverse events reported.Use of HMG-CoA reductase inhibitors in patients with elevated AST resulted in normalization of AST levels. HMG-CoA reductase inhibitors were safe in patients with mildly elevated AST. This may translate to use of HMG-CoA reductase inhibitors in diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
